SLXN
NASDAQ · Biotechnology
Silexion Therapeutics Corp
$1.20
-0.02 (-1.64%)
Financial Highlights (FY 2025)
Revenue
2.24M
Net Income
-331,103
Gross Margin
58.4%
Profit Margin
-14.8%
Rev Growth
-3.1%
D/E Ratio
0.51
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 58.4% | 58.4% | 58.4% |
| Operating Margin | -15.9% | -16.2% | -13.2% |
| Profit Margin | -14.8% | -11.6% | -10.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.24M | 2.11M | 2.20M |
| Gross Profit | 1.31M | 1.23M | 1.28M |
| Operating Income | -355,497 | -342,621 | -289,842 |
| Net Income | -331,103 | -245,653 | -236,110 |
| Gross Margin | 58.4% | 58.4% | 58.4% |
| Operating Margin | -15.9% | -16.2% | -13.2% |
| Profit Margin | -14.8% | -11.6% | -10.7% |
| Rev Growth | -3.1% | +9.8% | -1.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.93M | 1.69M | 1.65M |
| Total Equity | 3.83M | 4.12M | 3.71M |
| D/E Ratio | 0.51 | 0.41 | 0.44 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -455,957 | -486,512 | -478,296 |
| Free Cash Flow | -187,144 | -193,211 | -204,399 |